|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:United_States
|
|
gptkbp:available_on
|
generic version
|
|
gptkbp:brand
|
gptkb:Strattera
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:chemical_formula
|
C16 H18 F3 N
|
|
gptkbp:class
|
norepinephrine reuptake inhibitor
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
long-term treatment
|
|
gptkbp:condition
|
ADHD
|
|
gptkbp:contraindication
|
gptkb:Ophthalmology
gptkb:pheochromocytoma
severe cardiovascular disorders
|
|
gptkbp:counseling_services
|
avoid alcohol
take at the same time each day
monitor for suicidal thoughts
report any unusual changes in mood
|
|
gptkbp:dosage_form
|
gptkb:capsule
40 mg to 100 mg daily
|
|
gptkbp:effective_date
|
gptkb:2002
|
|
gptkbp:formulation
|
extended-release
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Strattera
|
|
gptkbp:ingredients
|
atomoxetine
|
|
gptkbp:interacts_with
|
antidepressants
MAO inhibitors
blood pressure medications
|
|
gptkbp:lifespan
|
5 to 20 hours
|
|
gptkbp:manufacturer
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_Kingdom
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:requires
|
gptkb:true
|
|
gptkbp:research_focus
|
pharmacogenomics
impact on quality of life
long-term safety
ADHD treatment efficacy
comparing with stimulants
effects on academic performance
effects on appetite
effects on family dynamics
effects on sleep patterns
effects on social functioning
effects on weight
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
fatigue
nausea
decreased appetite
insomnia
dry mouth
sexual dysfunction
|
|
gptkbp:used_for
|
gptkb:Attention_Deficit_Hyperactivity_Disorder
|
|
gptkbp:bfsParent
|
gptkb:Atomoxetine
gptkb:Concerta
gptkb:Shire_Pharmaceuticals
gptkb:Vyvanse
|
|
gptkbp:bfsLayer
|
6
|